Opdivo and Yervoy significantly increase the survival rate of patients with thyoracic mesothelioma!

Malignant thoracic mesothelioma (MPM) is a rare tumor that usually originates on the mesothelioma surface of the thoracic cavity.
mesothelioma may also originate on the surface of the peritoneum, the testicular membrane, or the heart bag.
the prognostication of MPM was poor, and the patient's mid-life was 6-18 months.
recent studies have shown that immunotherapy Opdivo (nivolumab) in combination with ipilimumab has improved survival rates in previously untreated patients with malignant thoracic mesothelioma (MPM).
in phase III OfCheckMate-743, Opdivo combined with Yervoy to reduce the risk of death by 26 percent, with a mid-total survival of 18.1 months and a medium overall survival of 14.1 months for standard platinum-based therapies.
two years of follow-up, 41 percent of patients treated with Opdivo's combined Yervoy combination survived, while 27 percent of those who received chemotherapy survived.
in mesothelioma, patients with non-epiderm-like cancers usually have a poor prognosis.
CheckMate-743 trial showed that Opdivo combined with Yervoy significantly improved survival rates in patients with non-epiderm and epiderm MPM. Dr Paul Baas, of the Netherlands Cancer Institute and the Department of Chest Oncology at Leiden University,
, said: "The five-year survival rate of malignant thoracic mesothelioma is less than 10%, an invasive form of cancer that is resistant to many clinical treatments.
we have shown for the first time that dual immunotherapy shows superior overall survival benefits compared to chemotherapy," he said.
Sabine Maier, of Bristol Myers Squibb, said: "For more than 15 years, new treatments have not been approved for patients with malignant thoracic mesothelioma that can extend survival.
we look forward to discussions with global health authorities in the coming months on the positive outcome of CheckMate-743."
.